Newsbot

V.F. (VFC) concluded the recent trading session at $19.86, signifying a -1.63% move from its prior days close.

Hopes for an economic reacceleration are helping to fuel a “rotation trade.”

OIH hits a fresh 52-week high as oil prices stay firm and momentum builds. Can the rally last amid high risk?

AI stocks flew high in 2025 despite year-end volatility. Palantir and Lam look overvalued, but opportunities remain.

Micron surged past Nvidia last year as AI-driven HBM chip demand lifted revenue and profits. Can it keep the edge in 2026 as Nvidia scales Blackwell?

Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to be a juggernaut for years to come.

After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.

VZ has outpaced its wireless industry over the past year as 5G upgrades, network slicing and new partnerships fuel growth despite debt and competition.

ONDS has surged nearly 600% in six months as it pivots to autonomous systems, but soaring costs and valuation raise exit questions.

Stocks have staged a remarkable rally since the Liberation Day lows, and Andrew Rocco believes the bull market still has plenty of room to run. Discover how the 1999 internet boom can help you capitalize on this powerful trend in 2026 and beyond.

ACRE made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 9th, 2026.

Semiconductor sales hit a record in November, with NVDA, MU, CRDO and ASYS set to gain from booming AI demand.

Merck is in talks to acquire RVMD, which could bolster its oncology pipeline, according to a Financial Times report.

Bed Bath & Beyond (BBBY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

KTOS has jumped 35.3% in a month on contract wins and rising unmanned system demand, but weaker ROIC and sector risks complicate the entry timing.

With the 2025 Q4 earnings season about to begin, we discuss how critical the overall earnings picture is to the stock market.

Medical services stocks like MEDP, EHAB and PGNY benefit from tech-driven care models even as staffing gaps pressure margins.

Liquidity catalysts will be debated for 2026, from both global (U.S. and non-U.S.) monetary authorities. It is not guaranteed to work for stocks like it did in 2025.

CRM shares are down 18% in a year, but AI momentum, enterprise expansion and discounted valuation suggest Salesforce may still be worth holding.

JPMorgans Q4 earnings preview shows strength in trading and lending, but expenses and valuation may weigh on investor sentiment.

BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset mounting generic pressure

ExxonMobil warns that upstream earnings face pressure from lower oil prices, but its integrated model boosts refining gains to cushion profitability.

ABBVs Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humiras past loss of exclusivity.

GS expects a 46-cent EPS boost in 4Q25 as it exits the Apple Card, releasing reserves amid a 24-month transition of the program to JPMorgan.

TransMedics, KORU Medical Systems and Cardinal Health beat the S&P 500 as execution, earnings visibility and company-specific catalysts drove gains.

Amazons AWS posts its fastest growth since 2022 as AI demand surges, with a $200 billion backlog and heavy investment fueling 2026 optimism.

Between alarming slowdowns in growth and the financial strain of expansion into the competitive food delivery market, JDs "cheap" share price may be warranted.

CRM shares are down 18% in a year, but AI momentum, enterprise expansion and discounted valuation suggest Salesforce may still be worth holding.

CIEN and CMC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on January 9th, 2026.

EPD beat its industry with a 6% yearly gain, backed by inflation-linked contracts and capital returns, but valuation and leverage argue for patience.

Goldman Sachs Research predicts US stocks will rally again in 2026 amid solid economic growth and continued easing from the Fed.

Baidu edges ahead of Uber in the AV race, backed by global robotaxi rollout, stronger earnings outlook and valuation.

ACRE, STEP and ADEA made it to the Zacks Rank #1 (Strong Buy) income stocks list on January 9th, 2026.

AXILs shares surge after Q2 results showed higher revenue, improved operating income, and expanding retail momentum despite margin pressure.